Company Growth (employees)
ResMed was founded in 1989 and is headquartered in San Diego, US
ResMed Office Locations
ResMed has offices in San Diego, Kontich, Espoo, Moissy-Cramayel and in 24 other locations
San Diego, US (HQ)
9001 Spectrum Center Blvd
Rochester, US
1200 Brooks Ave
Singapore, SG
8 Loyang Cres
Hong Kong, HK
132 Nathan Rd
Guangzhou Shi, CN
Jian She Liu Ma Lu
Shanghai, CN
Wagas （ Shan Xi Bei Lu ）
ResMed Data and Metrics
ResMed Financial Metrics
ResMed's revenue was reported to be $1.8 b in FY, 2016 which is a 10% increase from the previous period.
USD
Revenue (FY, 2016) | 1.8 b |
Revenue growth (FY, 2015 - FY, 2016), % | 10% |
Gross profit (FY, 2016) | 1.1 b |
Gross profit margin (FY, 2016), % | 58% |
Net income (FY, 2016) | 352.4 m |
EBIT (FY, 2016) | 429 m |
Market capitalization (21-Jul-2017) | 11.1 b |
Cash (30-Jun-2016) | 731.4 m |
EV | 11.3 b |
ResMed's current market capitalization is $11.1 b.
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 1.6 b | 1.7 b | 1.8 b |
Revenue growth, % | 8% | 10% | |
Cost of goods sold | 667.5 m | 772.2 m | |
Gross profit | 1 b | 1.1 b | |
Gross profit Margin, % | 60% | 58% | |
R&D expense | 118.7 m | ||
General and administrative expense | 488.1 m | ||
Operating expense total | 602.2 m | 637.5 m | |
EBIT | 409.2 m | 429 m | |
EBIT margin, % | 24% | 23% | |
Interest expense | 5.8 m | 11.2 m | |
Interest income | 26.2 m | ||
Pre tax profit | 435.9 m | 439.6 m | |
Income tax expense | 83 m | 87.2 m | |
Net Income | 345.3 m | 352.9 m | 352.4 m |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Cash | 905.7 m | 717.2 m | 731.4 m |
Inventories | 165.4 m | 246.9 m | 224.5 m |
Current Assets | 1.6 b | 1.4 b | 1.4 b |
PP&E | 434.3 m | 387.8 m | 384.3 m |
Goodwill | 1.1 b | ||
Total Assets | 2.4 b | 2.2 b | 3.3 b |
Accounts Payable | 85.4 m | 81.1 m | 92.6 m |
Total Debt | 300.8 m | 300.6 m | 875 m |
Current Liabilities | 269.6 m | 267.3 m | 638.6 m |
Non-Current Liabilities | 333.2 m | 329.7 m | 925.6 m |
Total Liabilities | 602.7 m | 597 m | 1.6 b |
Additional Paid-in Capital | 1.1 b | 1.2 b | 1.3 b |
Retained Earnings | 1.8 b | 2 b | 2.2 b |
Total Equity | 1.8 b | 1.6 b | 1.7 b |
Debt to Equity Ratio | 0.2 x | 0.2 x | 0.5 x |
Debt to Assets Ratio | 0.1 x | 0.1 x | 0.3 x |
Financial Leverage | 1.3 x | 1.4 x | 1.9 x |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | 345.3 m | 352.9 m | 352.4 m |
Depreciation and Amortization | 73.5 m | 73.1 m | 86.8 m |
Accounts Receivable | (35 m) | (28 m) | (27.3 m) |
Cash From Operating Activities | 391.3 m | 383.2 m | 547.9 m |
Purchases of PP&E | (72.7 m) | (62.5 m) | (58.5 m) |
Cash From Investing Activities | (95 m) | (143.1 m) | (1.1 b) |
Dividends Paid | (141.5 m) | (157.3 m) | (168.1 m) |
Cash From Financing Activities | (297.3 m) | (255.8 m) | 612.6 m |
Interest Paid | 6.1 m | 5.8 m | 11.2 m |
Income Taxes Paid | 90.2 m | 48.5 m | 69 m |
| USD | Y, 2016 |
|---|---|
EV/EBIT | 26.2 x |
EV/CFO | 20.5 x |
Revenue/Employee | 423.7 k |
Debt/Equity | 0.5 x |
Debt/Assets | 0.3 x |
Financial Leverage | 1.9 x |
ResMed Market Value History
ResMed Median Salaries
Source: 31 public H-1B filings from ResMed
